Experts in developing gene therapies for inherited retinal disorders
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy.
The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.